Baidu
map

ACC/AHA 新胆固醇治疗指南被指扩大了他汀类药物的适应症人群

2013-11-19 MedSci MedSci原创

  上周ACC/AHA发布了一项《2013ACC/AHA降低成人动脉粥样硬化心血管风险胆固醇治疗指南》,指南推荐用一种新的风险评估公式计算患者10年心血管风险。然而,就在今天的AHA年会上,该评估方法引起了巨大争议。据纽约时报报道,布里格姆妇女医院的Paul Ridker 和Nancy Cook 医生在三项大规模一级预防队列研究中发现,ACC/AHA指南推荐的新计算方法过高估计

  上周ACC/AHA发布了一项《2013ACC/AHA降低成人动脉粥样硬化心血管风险胆固醇治疗指南》,指南推荐用一种新的风险评估公式计算患者10年心血管风险。然而,就在今天的AHA年会上,该评估方法引起了巨大争议。据纽约时报报道,布里格姆妇女医院的Paul Ridker 和Nancy Cook 医生在三项大规模一级预防队列研究中发现,ACC/AHA指南推荐的新计算方法过高估计了患者的心血管风险75%-150%。

  根据新的胆固醇治疗指南,没有心血管疾病或糖尿病但LDL-C在70-189mg/dl 和10年动脉粥样硬化心血管疾病风险7.5%以上的患者,均是他汀类药物的适应症。

  Ridker医生表示他很高兴指南关注他汀和临床医生的实际应用,也非常支持新的指南,相信指南会朝着为病人提供最佳管理的方向进行。但是无论何时,发展一个新的临床风险评估工具,其中最重要的一环就是在更广泛的人群中证明其有效性,也就是说,预测风险与实际风险需要进行验证。

 


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1934752, encodeId=26231934e5294, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sun Apr 27 01:45:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044342, encodeId=efd92044342db, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Jan 23 20:45:00 CST 2014, time=2014-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267176, encodeId=4bcb126e1765a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Nov 21 07:45:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324861, encodeId=07101324861d6, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Nov 21 07:45:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336678, encodeId=10e313366e80f, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Thu Nov 21 07:45:00 CST 2013, time=2013-11-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1934752, encodeId=26231934e5294, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sun Apr 27 01:45:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044342, encodeId=efd92044342db, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Jan 23 20:45:00 CST 2014, time=2014-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267176, encodeId=4bcb126e1765a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Nov 21 07:45:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324861, encodeId=07101324861d6, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Nov 21 07:45:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336678, encodeId=10e313366e80f, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Thu Nov 21 07:45:00 CST 2013, time=2013-11-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1934752, encodeId=26231934e5294, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sun Apr 27 01:45:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044342, encodeId=efd92044342db, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Jan 23 20:45:00 CST 2014, time=2014-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267176, encodeId=4bcb126e1765a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Nov 21 07:45:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324861, encodeId=07101324861d6, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Nov 21 07:45:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336678, encodeId=10e313366e80f, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Thu Nov 21 07:45:00 CST 2013, time=2013-11-21, status=1, ipAttribution=)]
    2013-11-21 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=1934752, encodeId=26231934e5294, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sun Apr 27 01:45:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044342, encodeId=efd92044342db, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Jan 23 20:45:00 CST 2014, time=2014-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267176, encodeId=4bcb126e1765a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Nov 21 07:45:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324861, encodeId=07101324861d6, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Nov 21 07:45:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336678, encodeId=10e313366e80f, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Thu Nov 21 07:45:00 CST 2013, time=2013-11-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1934752, encodeId=26231934e5294, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sun Apr 27 01:45:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044342, encodeId=efd92044342db, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Jan 23 20:45:00 CST 2014, time=2014-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267176, encodeId=4bcb126e1765a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Nov 21 07:45:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324861, encodeId=07101324861d6, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Nov 21 07:45:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336678, encodeId=10e313366e80f, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Thu Nov 21 07:45:00 CST 2013, time=2013-11-21, status=1, ipAttribution=)]

相关资讯

ACCF/AHA:2013年ACCF/AHA心衰管理指南

根据美国心脏病学会基金会(ACCF)和美国心脏协会(AHA)联合制订的最新版心力衰竭治疗指南,心力衰竭已不再是死亡判决,而是可以通过治疗使部分患者增加数年有质量的寿命。联合指南编撰委员会主席、美国西北大学心脏病学系主任Clyde W. Yancy博士指出:“假如能在正确的时间,以正确的方式,对正确的患者采取最佳的治疗,那么死亡风险就能非常显著地降低,降低幅度可能多达50%。每给予10例患者正确的治

美ASCO/CAP联合指南:乳腺癌HER2检测

更新后的指南包括了医生与病人讨论HER2状态关键点的更为详细的推荐:例如HER2检测的原因,使用检测的类型,检测结果的解释,在疾病复发时可能需要复检。 美国临床肿瘤学会(ASCO)和美国病理学家协会(CAP)近日更新了一项联合指南,旨在提高浸润性乳腺癌患者HER2检测的准确性和报告。该指南的更新是基于一项系统综述,给肿瘤科医生和病理科医生提供了以下内容的详细推荐:如何检测HER2过表达,如何解释

ESCMID全新艰难梭菌感染(CDI)治疗指南发布

10月29日,欧洲临床微生物和感染病学会(ESCMID)更新了艰难梭菌感染(CDI)治疗指南,并对抗生素、毒素-结合树脂和聚合物、免疫疗法、益生菌、粪菌以及肠道细菌移植等各种治方法进行了综述。CDI已经超过抗甲氧西林金黄色葡萄球菌,是目前医院内获得性感染的主要原因。在美国和欧洲研制了新的药物(例如,非达霉素)用于治疗CDI后,使用和现行抗生素效果相当的新药的需求正在增加。新指南对目前在临床实践中广

美国内分泌学会发布2013多囊卵巢综合征(PCOS)的诊断和治疗指南

  美国内分泌学会(The Endocrine Society)专家小组近日发布了多囊卵巢综合征(PCOS)诊断和治疗的最新临床实践指南。由于PCOS的发病机制至今尚不明确并且其临床特征多不典型,因此成为近年来生殖医学和美国国立卫生研究院(NIH)的各大会议上讨论的热点话题之一。来自美国宾夕法尼亚州立大学医学院的Richard S. Legro博士(PCOS指南制定专家小组组长)在指南的新闻发

从国情出发,全面开展高血压患者教育

目前,我国高血压患者超过2.6亿人,且知晓率、治疗率和控制率较低,其原因是多方面的。与时常出现的伪科学以及不规范的健康宣传、患者自身健康知识的缺乏、对高血压的危害和长期治疗重要性的认识不足有关。因此,制订权威且可操作的国家级高血压患者教育指南,并以此开展科学规范的患者健康教育十分必要。 2012年,在中华人民共和国国家卫生和计划生育委员会(卫计委)支持下,中国高血压联盟与国家心血管病

2013年ESC稳定性冠状动脉疾病管理指南

Guidelines summarize and evaluate all evidence available, at the time of the writing process, on a particular issue with the aim of assisting physicians in selecting the best management strategies for

Baidu
map
Baidu
map
Baidu
map